Myriad Genetics Inc. MYGN
Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 1995 · data as of November 13, 2026
Myriad Genetics Inc. (MYGN) is a healthcare company listed in the US with a market value of about $543M. In the twelve months to September 30, 2026 it had revenue of $804M and net income of -$129M, a net margin of -16.1%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 8% a year, a 5-year average ROIC of -24%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 89% below the current price.
About Myriad Genetics
Myriad Genetics is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances, IPO year 1995. Revenue went from $723M in 2015 to $824M in 2025, growth of about 1.3% a year. It was profitable in 4 of the last 10 years in our data. Its share count rose by 15% over three years (dilution for shareholders). It spends 13% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $804M | $824M | $838M | $753M | $678M | $691M | $557M | $851M | $744M | $771M | $754M |
| Net income | -$129M | -$366M | -$127M | -$263M | -$112M | -$27M | -$224M | $5M | $133M | $17M | $117M |
| Free cash flow | -$38M | — | -$19M | -$121M | -$152M | $600000 | — | $75M | $108M | $100M | $161M |
| EPS (diluted) | $-1.35 | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 | $-2.99 | $0.06 | $1.85 | $0.25 | $1.60 |
| Net margin | -16.1% | -44.4% | -15.2% | -35.0% | -16.5% | -3.9% | -40.1% | 0.5% | 17.9% | 2.3% | 15.6% |
| ROIC | — | -62.1% | -11.6% | -21.7% | -10.9% | -14.2% | -19.5% | 0.4% | 9.9% | 4.0% | 15.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $5.90, 4% above the current price; targets range from $3.80 to $8.00; the consensus rating is “Hold”; expected EPS is $-0.69 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Myriad Genetics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 89% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Myriad Genetics pay a dividend?
Not currently.
Is Myriad Genetics a good stock to buy?
We do not give buy or sell advice. Myriad Genetics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.